Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
WIMMlogo-justsquare

Doug Higgs (WIMM) and Peter Donnelly (WTCHG) have been awarded a collaborative Wellcome Trust Strategic grant (~£3M) to develop a systematic approach to understanding the biology underpinning GWAS hits.  Our aim is to establish a pipeline for identifying causative SNPs and the genes they regulate.  Initially we will study red cell traits (with David Roberts and Dominic Kwiatowski), type 2 diabetes (with Mark McCarthy and Anna Gloyn) and multiple sclerosis (with Lars Fugger and Calli Dendrou).  The pipelines for analysing RNA expression, chromatin modifications,  and chromosme conformation capture will be developed by Doug Higgs, Anna Gloyn and Jim Hughes and we intend that these will ultimately be generally available to others studying human genetic and epigenetic diseases in the WIMM.  Tudor Fulga and Tatjana Sauka Spengler will help develop the tools for genome editing of primary cells and iPS lines (from Zam Cader).  High end statistical genetics and computational biology will be undertaken by Peter Donnelly and Gil McVean.  Hopefully this will be an exciting new venture for the WIMM.

Similar stories

Research unpicks why immune responses decrease with age

MRC MHU

Study reveals what happens to blood cell production during the ageing process, which could help identify new therapeutic targets.

Study finds new human blood disorder

MRC MHU RDM

The Patel Group have discovered a new human disease caused by formaldehyde accumulation in cells

Researchers target previously unknown ‘genetic vulnerability’ in breast cancer cells

MRC MHU NDM RDM

New Nature paper reveals discovery of a genetic vulnerability in nearly 10% of breast cancer tumours and how this can be targeted to selectively kill cancer cells.

Developing a rapid and cost-effective way to identify newborns at risk of leukaemia

MRC MHU

MRC WIMM researchers have developed a new method to quickly identify cancerous cells in babies at risk of leukaemia. The team hope that the new protocol could make rapid testing more accessible for clinical laboratories around the globe.